Epidemiology, medical outcomes and costs of catheter-related bloodstream infections in intensive care units of four European countries: literature- and registry-based estimates von Tacconelli, E, Smith, G, Hieke, K, Lafuma, A, Bastide, P

Volltext

Cost-of-illness of patients with chronic hand eczema in routine care: results from a multicentre study in Germany von Augustin, M., Kuessner, D., Purwins, S., Hieke, K., Posthumus, J., Diepgen, T.L.

Volltext

The links between joint damage and disability in rheumatoid arthritis von Scott, D. L., Pugner, K., Kaarela, K., Doyle, D. V., Woolf, A., Holmes, J., Hieke, K.

Volltext

Capecitabine (Xeloda™) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma von Twelves, C, Boyer, M, Findlay, M, Cassidy, J, Weitzel, C, Barker, C, Osterwalder, B, Jamieson, C, Hieke, K

Volltext

Nonlinear operation of the Y -branch switch: Ballistic switching mode at room temperature von Hieke, Katharina, Ulfward, Mikael

Volltext

Costs of Toxicity during Chemotherapy with CHOP, COP/CVP, and Fludarabine von Herold, M., Hieke, K.

Volltext

Electron Waveguide Y-branch Switches Controlled by Pt/GaAs Schottky Gates von Forsberg, E, Hieke, K

Volltext

PSS21 COST OF ILLNESS OF WORK-RELATED CHRONIC HAND ECZEMA IN GERMANY von Diepgen, T, Hieke, K

Volltext

PSS29 SOCIETAL COSTS OF SEVERE CHRONIC HAND ECZEMA (CHE) IN GERMANY von Hieke, K, Diepgen, T

Volltext

Economic analysis of adjuvant therapy with interferon alpha-2a in stage II malignant melanoma von Lafuma, A., Dreno, B., Delaunay, M., Emery, C., Fagnani, F., Hieke, K., Bonerandi, J.-J., Grob, J.-J.

Volltext

The costs of rheumatoid arthritis: an international long-term view von Pugner, Klaus M., Scott, David I., Holmes, Jeremy W., Hieke, Klaus

Volltext

PCN23 ADDING RITUXIMAB TO STANDARD CHEMOTHERAPY IS COST NEUTRAL AND CLINICALLY SUPERIOR IN ADVANCED STAGE NON-HODGKIN'S LYMPHOMA (NHL) von Hieke, K, Herold, M

Volltext

Evaluation of non-medical costs associated with visual impairment in four European countries : France, Italy, Germany and the UK von LAFKMA, Antoine, BREZIN, Antoine, LOPATRIEIIO, Stefania, HIEKE, Klaus, HUTCHINSON, Julia, MIMAUD, Viviane, BERDEAUX, Gills

Volltext

PCN16 ADDING RITUXIMABTO STANDARD CHEMOTHERAPY APPEARS DOMINANT VS. CHEMOTHERAPY ALONE IN ADVANCED STAGE NHL—INTERIM RESULTS FROM A RANDOMIZED CLINICAL TRIAL (RCT) von Hieke, K, Herold, M

Volltext

PCN37 IMPACT OF HEALTH CARE REFORMSAND CHANGING PAYMENT MECHANISMS ON HEALTH ECONOMIC EVALUATIONS IN GERMANY von Hieke, K, Grothey, A

Volltext

PCN21 TREATMENT COST OF COLORECTAL CANCER CHEMOTHERAPIES IN GERMANY von Hieke, K, Grothey, A

Volltext

PCN69 COST-EFFECTIVENESS OF ADDING CAPECITABINE TO TRASTUZUMAB AND DOCETAXEL AS FIRST LINE THERAPY FOR PATIENTS WITH HER-2-POSITIVE METASTATIC BREAST CANCER (HER2+MBC)—RESULTS FROM... von Hieke, K, Ducournau, P, de Reydet de Vulpillières, F

Volltext

PNM19 RESOURCE UTILISATION AND COSTS OF PATIENTS WITH SPINAL CORD INJURY (SCI) AFTER INITIAL REHABILITATION von Hieke, K, Hoser, H

Volltext

PCN14 COST IMPLICATIONS OF ORAL TREATMENT OF COLORECTAL CANCER IN GERMANY von Hieke, K, Grothey, A

Volltext

PCN94 CAPECITABINE + OXALIPLATIN (XELOX) VS. 5-FU/LV + OXALIPLATIN (FOLFOX4) IN THE ADJUVANT TREATMENT OF PATIENTS WITH COLON CANCER (ACC): COMPARISON OF DIRECT MEDICAL AND SOCIETA... von Winterhalder, R, Delmore, G, van Lier, M, Urspruch, A, Hieke, K

Volltext